General Report

The antibiotic resistance and treatment strategies of Helicobacter pylori in children in Wuxi

  • Danli ZHOU ,
  • Yan WANG ,
  • Jingjing LING ,
  • Lan GU ,
  • Meiling HAN ,
  • Qiong LIN
Expand
  • Wuxi Children's Hospital, Wuxi 214023, Jiangsu, China

Received date: 2021-10-08

  Online published: 2022-12-06

Abstract

Objective To analyze the infection and drug resistance of Helicobacter pylori (Hp) in outpatients in Wuxi, Jiangsu province, and to explore the strategy of rational use of antibiotics. Methods The clinical data of children who underwent gastroscopy in gastroenterology outpatient department due to upper gastrointestinal symptoms from December 2018 to July 2021 were retrospectively analyzed. Results Gastric antral mucosa samples were collected from 716 children, including 392 boys and 324 girls. The median age was 11.0 (9.0-13.0) years, and there were 454 children ≤12 years old and 262 children >12 years old. Hp culture was positive in 260 children (36.3%), including 132 boys and 128 girls. There were 148 children ≤12 years old and 112 children >12 years old. The positive rate of Hp in children >12 years old (42.7%) was significantly higher than that in children ≤12 years old (32.6%), and the difference was statistically significant (P<0.05). The results of drug susceptibility test of 260 Hp strains showed that 10.4% (27/260) of the strains were sensitive to all six antimicrobial agents. The drug resistance rates of metronidazole, clarithromycin and leofloxacin were 75.4% (196/260), 37.7% (98/260) and 20.8% (54/260), respectively. No strains resistant to furazolidone, amoxicillin and tetracycline were found. Seventy-six patients were resistant to two antimicrobial agents, including 45 patients with dual resistance to clarithromycin and metronidazole, 11 to clarithromycin and levofloxacin, and 20 to metronidazole and levofloxacin. Nineteen children were resistant to clarithromycin, metronidazole and levofloxacin. Conclusions The positive rate of Hp culture in children of Wuxi region increased significantly with age. The drug resistance rate of Hp to metronidazole is very high. Metronidazole should be avoided in empirical treatment, and tetracycline and furazolidone can be considered to replace metronidazole.

Cite this article

Danli ZHOU , Yan WANG , Jingjing LING , Lan GU , Meiling HAN , Qiong LIN . The antibiotic resistance and treatment strategies of Helicobacter pylori in children in Wuxi[J]. Journal of Clinical Pediatrics, 2022 , 40(12) : 925 -929 . DOI: 10.12372/jcp.2022.21e1407

References

[1] Mi?ak Z, Hojsak I, Homan M. Review: Helicobacter pylori in pediatrics[J]. Helicobacter, 2019, 24(Suppl 1): e12639.
[2] 中华医学会儿科学分会消化学组. 儿童幽门螺杆菌感染诊治专家共识[J]. 中华儿科杂志, 2015, 53(7): 496-498.
[3] Hunt RH, Xiao SD, Megraud F, et al. Helicobacter pylori in developing countries. World Gastroenterology Organisation Global Guideline[J]. J Gastrointestin Liver Dis, 2011, 20(3): 299-304
[4] Brennan D, O'Morain C, Mcnamara D, et al. Molecular detection of antibiotic-resistant Helicobacter pylori[J]. Methods Mol Biol, 2021, 2283: 29-36.
[5] 钟华敏, 骆明勇, 谢永强, 等. 某地区儿童幽门螺杆菌感染病原学研究[J]. 国际检验医学杂志, 2011, 32(13): 3.
[6] Shu X, Ping M, Yin G, et al. Investigation of Helicobacter pylori infection among symptomatic children in Hangzhou from 2007 to 2014: a retrospective study with 12,796 cases[J]. PeerJ, 2017, 5(Suppl 1): e2937.
[7] Savoldi A, Carrara E, Graham DY, et al. Prevalence of antibiotic resistance in Helicobacter pylori: a systematic review and meta-analysis in World Health Organization regions[J]. Gastroenterology, 2018, 155(5): 1372-1382.
[8] 李东丹, 周锦, 王国丽, 等. 儿童幽门螺杆菌耐药情况及影响因素分析[J]. 中华实用儿科临床杂志, 2019, 34(19): 1450-1453.
[9] 陈競芳, 卓志强, 王晓冬, 等. 厦门市学龄期儿童幽门螺杆菌感染耐药性及4种治疗方案疗效[J]. 中华医院感染学杂志, 2020, 30(19): 3031-3035.
[10] 周颖, 王玉环, 芦军萍. 上海市单中心儿童幽门螺杆菌不同治疗方案根除率及其耐药率的横断面调查[J]. 中国循证儿科杂志, 2019, 14(2): 81-86.
[11] 丁建, 钟婧, 钮萍萍, 等. 湖州地区青少年儿童幽门螺杆菌感染及耐药情况[J]. 国际流行病学传染病学杂志, 2017, 44(6): 378-381.
[12] Jones NL, Koletzko S, Goodman K, et al. Joint ESPGHAN/NASPGHAN Guidelines for the management of Helicobacter pylori in children and adolescents (update 2016)[J]. J Pediatr Gastroenterol Nutr, 2017, 64(6): 991-1003.
[13] Zhou Y, Ye Z, Wang Y, et al. Comparison of four different regimens against Helicobacter pylori as a first-line treatment: a prospective, cross-sectional, comparative, open trial in Chinese children[J]. Helicobacter, 2020, 25(2): e12679.
[14] 卢华君, 赵忠艳, 陈旺强, 等. 儿童感染幽门螺杆菌的耐药性及治疗分析[J]. 中国全科医学, 2015, 18(31): 3876-3880.
[15] 陈溢, 余金丹, 赵泓, 等. 儿童幽门螺杆菌感染根除治疗疗效分析[J]. 中国实用儿科杂志, 2018, 33(4): 291-296.
[16] Song Z, Fu W, Zhou L. Cefuroxime, levofloxacin, esomeprazole, and bismuth as first-line therapy for eradicating Helicobacter pylori in patients allergic to penicillin[J]. BMC Gastroenterol, 2019, 19(1): 132.
[17] Fu W, Song Z, Zhou L, et al. Randomized clinical trial: esomeprazole, bismuth, levofloxacin, and amoxicillin or cefuroxime as first-line eradication regimens for Helicobacter pylori infection[J]. Dig Dis Sci, 2017, 62(6): 1580-1589.
Outlines

/